Navigation Links
A Combined Heart Pill-developed by Dr. Reddy’

Dr. Reddy’s, the Indian pharma giant has decided to join hands with the University of Auckland, //New Zealand to begin Global trials of a new fixed dose combination or “polypills” to prevent strokes and heart attacks.

The polypill will combine four drugs- aspirin, statin(to reduce cholesterol) and two drugs to prevent hypertension. The trial will check the reliability of the pill when it comes to safety and its effectiveness when consumed as one pill.

Investments of Dr. Reddy’s in the trial would come up to $7.5 million, and The Health Research Council, New Zealand has invested U.S. $241,055.

Dr. Reddy’s has initiated the trial six months ago, Satish Reddy, COO and managing director of Dr. Reddy’s said, “Since all medicines in the polypill are already prescribed to heart attack patients, we don’t anticipate any problem with polypill trial.”

Anyway, the plan of having a global trial will assess the success of using the polypill in different populations. The trial will begin by the second quarter of 2007, and would involve 600 people from five continents.

Apart from people from India and New Zealand, the other countries involved in the global trial would be South Africa, China, Australia, Brazil, the United Kingdom and the United States.

It took three years for the drug company to formulate this pill. Mr.Reddy’s claims this pill to be “single most important initiative of the decade” by his firm. He also said, “We should be able to introduce the drug for secondary indication [prescriptions to stroke/heart attack patients] by mid-2007.”

Affordability of the polypill

The cost of this pill is taken to prime importance since it is to be used in developing countries. Dr.Reddy’s assured, “Our intention is to see that one month’s medication costs less than Rs. 100 [U.S. $2.20]. The combination is not going to bring us big money, but it will help the patients as they get all four pills co mbined.”

Trials at Global Level

Professor Anthony Rodgers working at the University of Auckland’s, belonging to the clinical trials research unit is going to lead the trial. He has been an advisory to WHO and is also a world-renowned clinical trial expert.

Prof. Rodgers claims that this combined pill will prove to be more effective than four medicines. He said, “Research shows that people with chronic diseases, like heart disease, take only half their medications, they forget, or they feel well, so think they don’t need to take their pills. However, that creates a gap in their treatment, which can have serious consequences for some patients.”

Thus he believes that this oil is a more practical and easy solution to cardiac ailments.

Prof. Rodgers said that the first trial would involve 5000 people moderately prone to cardiac ailments. He said, “The first trial will confirm whether the polypill lowers blood pressure and cholesterol, if it goes ahead, this second trial would confirm the pill’s ability to prevent heart attacks and strokes.”
Source-Medindia
KOM
'"/>




Related medicine news :

1. Combined scan gives exact cancer diagnosis
2. A Protein-Rich Diet Combined With Exercise Found To Be More Effective In Weight Loss
3. Combined modality approach for effective treatment and enhanced survival in bile duct cancer
4. Vision Loss in Elderly Caused By Combined Effect of Genes and Bacterium
5. Exercise Combined with Dialysis Yields Better Results
6. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
7. A Combined Research for Producing Chlamydia Vaccine Begins
8. Combined Ingredients may Cut Cholesterol Levels
9. Combined Imaging Approach may Provide Better Identification of Difficult-to-diagnose Brain Clots
10. Combined Imaging Approach may Be Effective in Diagnosing Some Brain Clots
11. One in Three Heart Attack Patients Have No Chest Pains
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/22/2017)... ... May 22, 2017 , ... OSF Ventures, the corporate investment ... an early stage company in San Francisco that has developed software to individualize ... Innovation Fund acted as the lead investor in the round. , Medicine ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... ABC Financial Services and financial systems. , Dozens of clubs using ... that are electronically processed through GetLinked into their club’s accounting system , The ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... together a cross-disciplinary group of scholars, policymakers, and activists wanting to address equity ... Equity is the third book from a recent series of from this ...
(Date:5/21/2017)... ... ... Following the tragic and widely publicized death of Rory Staunton, 12, from ... follow a protocol to quickly identify and treat the condition. , The mandate ... have saved Rory or anyone else’s life. , Now, five years after the ...
(Date:5/19/2017)... NC (PRWEB) , ... May 19, 2017 , ... ... the Charlotte health community, Queens University of Charlotte recently began recruitment efforts for ... program’s curriculum arms students with the skills, knowledge and expertise to approach and ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... Company, and STI Technologies Limited to lower diabetes healthcare ... Through STI,s innoviCares card, which is available throughout all ... DarioHealth customers will be eligible for additional savings when ...
(Date:5/4/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... today announced that the Company,s first quarter 2017 financial ... May 11, 2017, and that the Company will host ... PT that afternoon. Management will provide an overview of ...
(Date:5/3/2017)... , May 3, 2017  Kalorama Information notes ... nine percent next year and this is projected ... hematopoietic stem cell (HSCT) or bone marrow transplants ... technologies are well-suited for this task. This according ... publisher Kalorama Information. The various PCR-based methodologies, Sanger ...
Breaking Medicine Technology: